Cardiac biomarkers market seen reaching $57.64B by 2035

The global cardiac biomarkers market is projected to climb from $17.78 billion in 2025 to $57.64 billion by 2035, driven by high-sensitivity troponin adoption, faster point-of-care testing and rising cardiovascular disease burden. The shift could reshape emergency care, lab purchasing and reimbursement across the U.S., Europe and fast-growing Asia-Pacific markets.

Why it matters: - Cardiac biomarker testing is moving from routine lab work into a faster, more protocol-driven part of emergency and chronic heart care. - The shift affects hospital throughput, diagnosis speed, reimbursement decisions and where testing is performed, including ambulances, urgent care and home monitoring. - The market’s growth reflects rising cardiovascular disease burden and broader use of biomarkers in myocardial infarction, heart failure, cardiotoxicity surveillance and perioperative risk assessment.

What happened: - Market Research Future projects the global cardiac biomarkers market will reach $57.64 billion by 2035, up from $17.78 billion in 2025. - The forecast implies a 12.4% compound annual growth rate from 2026 to 2035. - The market enters 2026 at $20.13 billion, after expanding from $11.48 billion in 2021. - The report ties the market’s growth to high-sensitivity assay conversion, point-of-care rule-out protocols and rising cardiovascular disease prevalence. - Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher, QuidelOrtho and Thermo Fisher Scientific are expanding cardiac biomarker offerings across central labs and decentralized settings.

The details: - High-sensitivity immunoassays are replacing conventional troponin I and CK-MB testing across many laboratories. - The European Society of Cardiology’s 0/1-hour algorithm requires high-sensitivity cardiac troponin and has been implemented in more than 78% of surveyed EU tertiary centers. - Troponins accounted for 55.6% of market revenue in 2025. - Natriuretic peptides generated $3.42 billion in 2025 and remain the second major market segment. - Ischemia-modified albumin is projected to be the fastest-growing biomarker type through 2035 at a 9% CAGR. - Myoglobin, growth-differentiation factor-15, galectin-3 and soluble ST2 are emerging as niche and research-focused markers. - Central laboratory testing was the largest location segment in 2025 at $9.76 billion. - Point-of-care testing is the fastest-growing location segment, with demand rising in emergency departments, ambulances and primary care. - Myocardial infarction was the largest application segment in 2025 with a 5% share. - Acute coronary syndrome is the fastest-growing application segment through 2035. - Congestive heart failure testing reached $4.27 billion in 2025. - Hospitals were the largest end-user segment in 2025. - Diagnostic laboratories generated $4.63 billion in 2025. - Home healthcare is the fastest-growing end-user segment as remote monitoring programs expand. - North America led the market with 39.3% of global revenue in 2025. - Europe was the second-largest regional market at $4.91 billion in 2025. - Asia-Pacific is the fastest-growing region, with a projected 13.4% CAGR through 2035. - South America was a $0.92 billion market in 2025. - The Middle East and Africa held about 3.8% of global share in 2025. - Abbott said it expanded i-STAT cartridge manufacturing capacity in January 2025. - Roche expanded its cardiac menu on the cobas pro system in September 2024 with extended NT-proBNP claims for heart failure monitoring. - Siemens Healthineers launched updated immunoassay software in June 2024 with automated 0/1-hour algorithm reporting. - QuidelOrtho completed integration of its cardiac immunoassay portfolio onto a unified VITROS service platform in November 2024.

Between the lines: - The competitive fight is shifting from single-assay performance to workflow integration, installed base, reagent pull-through and point-of-care reach. - The report estimates the market is moderately concentrated, with an HHI near 1,180 and the top five suppliers controlling roughly 62% to 68% of revenue. - Regulatory and reimbursement changes are becoming as important as clinical demand in deciding which platforms win share. - Faster rule-out testing also gives hospitals an operations argument, not just a clinical one, because shorter turnaround times can ease emergency department congestion. - Asia-Pacific’s growth suggests the next phase of expansion will depend heavily on regulatory modernization and decentralized testing adoption.

What's next: - More growth is likely to come from novel prognostic markers, AI-enabled decision support and broader use of cardiotoxicity and pre-operative risk testing. - Vendors are expected to push deeper into emerging markets with decentralized platforms and into home heart-failure monitoring. - Reagent rental and consumables-as-a-service models may gain traction as buyers look for lower upfront costs and more predictable operating expenses. - The report expects cardiovascular testing to move further from episodic diagnosis toward continuous, algorithm-guided care by 2035.

The bottom line: - Cardiac biomarkers are becoming a faster, more distributed and more data-driven testing category, with the biggest gains likely to come from high-sensitivity assays and point-of-care workflows.